pandemic monovalent influenza vaccine

The **pandemic monovalent influenza vaccine** is a nonproprietary investigational A/H5N1 hemagglutinin antigen vaccine program evaluated in a Phase 2 randomized, observer-blind dose-finding trial. The trial evaluates one or two intramuscular administrations across antigen-dose and adjuvant-dose groups, including formulations containing CpG 1018 and aluminum hydroxide and an alum-only comparator formulation. CpG 1018 is intended to enhance innate immune activation through Toll-like receptor 9 and thereby augment vaccine-induced anti-hemagglutinin immune responses. The registered intervention name encompasses multiple dose/formulation arms rather than one uniquely identifiable finished vaccine product. ([anzctr.org.au](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=390124))

Other names

pandemic monovalent influenza vaccineinvestigational pandemic flu vaccine